Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC29HL
|
|||
| Drug Name |
Lu AF11167
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Phase 2 | [1] | |
| Company |
Lundbeck
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Phosphodiesterase 10A (PDE10) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Purine metabolism | |||
| Morphine addiction | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | cGMP effects | |||
| G alpha (s) signalling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03929497) Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms. U.S. National Institutes of Health. | |||
| REF 2 | PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?. Front Neurosci. 2021 Jan 20;14:600178. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.